Here are some of the main medicinal properties that have been investigated
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications increasingly prescribed in the UK for type 2 diabetes management and, more recently, for weight management in adults with obesity
Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
Altered daytime fluctuation pattern of plasminogen activator inhibitor 1 in type 2 diabetes patients with coronary artery disease: a strong association with persistently elevated plasma insulin, increased insulin resistance, and abdominal obesity
the 1 percent hair restoration solution shows initial follicular response at 90 days and full effect at 180 days